Jefferies Weighs In on Ultragenyx Pharma (RARE) Related to SIMD Abstracts
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Ultragenyx Pharma (RARE) Tops Q4 EPS by 1c
March 25, 2015 4:06 PM EDTUltragenyx Pharma (NASDAQ: RARE) reported Q4 EPS of ($0.52), $0.01 better than the analyst estimate of ($0.53).
For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.
... MoreCRT Capital Starts Ultragenyx Pharma (RARE) at Buy
March 24, 2015 4:29 PM EDTCRT Capital initiated coverage on Ultragenyx Pharma (NASDAQ: RARE) with a Buy rating and a price target of $90.00.
For an analyst ratings summary and ratings history on Ultragenyx Pharma click here. For more ratings news on Ultragenyx Pharma click here.
Shares of Ultragenyx Pharma closed at $59.96 yesterday.
... More